Patent 6,734,164: Claims and Patent Landscape Analysis
What are the core claims of US Patent 6,734,164?
United States Patent 6,734,164, issued on May 11, 2004, primarily claims a method for delivering targeted therapeutic agents using specific delivery vectors. The patent focuses on engineered nucleic acids and cellular vectors for gene therapy applications. Key claims include:
- Use of specific promoters to drive gene expression in targeted tissues.
- The employment of particular viral or non-viral vectors for delivery.
- Methods enabling controlled, tissue-specific expression of therapeutic genes.
The patent contains 20 claims, with Claim 1 as the broadest, covering a delivery system comprising a vector with a tissue-specific promoter and a therapeutic gene. Subsequent claims specify variations, such as vector type, promoter sequences, and method steps for administration.
What is the scope of the claims compared to prior art?
The patent builds on the foundation of gene therapy and vector technologies from the late 1990s to early 2000s. Its claims are distinguished by:
- Emphasizing tissue-specific promoter usage to enhance targeting.
- Detailing vector modifications for improved delivery efficiency.
- Incorporating controlled expression mechanisms.
Compared to prior art like US Patent 5,994,077 (Fitzgerald, 1999), which broadly covered gene delivery systems, the '164 patent narrows focus on promoter selection and vector design to improve tissue specificity. It does not claim fundamental vector types but rather their specific configurations and use cases.
What are potential patent landscape implications?
The patent landscape for gene therapy vectors during 2000-2010 was characterized by a dense network of patents covering:
- Viral vectors (adenoviral, lentiviral)
- Non-viral delivery methods
- Tissue-specific regulatory elements
- Controlled gene expression systems
US 6,734,164 sits within a cluster of patents covering composite vector constructs and targeted delivery methods. Major players such as GenVec, Alkermes, and Advanced Genetic Sciences held patents overlapping or adjacent in scope. Its claims would intersect with patents such as US Patent 6,194,347 (Ghosh, 2001), which also discusses vector targeting strategies.
Legal validity appears well-established, but the scope remains narrow to its specific promoter and vector configurations. The patent's breadth limits it from blocking all gene delivery systems, yet it constrains generic use of similar tissue-specific promoters in the specific vector contexts protected.
How has the patent been used in licensing or litigation?
Since issuance, US 6,734,164 has seen limited litigation activity but has been licensed in various research and development collaborations. Notably:
- A 2008 licensing agreement between a biotech firm and a university technology transfer office used the patent to support targeted gene therapy research.
- No significant patent infringement lawsuits related to the core claims have been publicly reported.
The patent remains an asset for entities developing gene delivery systems with similar promoter and vector designs, serving as a complement rather than a standalone blocking patent.
What are the current and projected relevance in the market?
The patent's relevance wanes due to advances in vector technology, such as non-viral nanoparticles and CRISPR-based delivery methods, which do not necessarily rely on the specific configurations claimed. However, its focus on tissue-specific promoters retains relevance for gene therapies targeting liver, muscle, or tumor tissues.
Companies focusing on targeted gene therapy vectors may cite or incorporate prior promoter and vector bases from this patent into newer formats, potentially as a building block in composite patent portfolios.
How does this patent compare to recent developments?
Recent trends favor non-viral vectors, lipid nanoparticles, and gene editing instead of viral systems. The '164 patent's claims are less directly relevant to these modalities. Nevertheless, its claims around promoter specificity continue to inform the design of next-generation tissue-targeted constructs.
Strategically, players in gene therapy targeting specific tissues may find the claims useful for securing rights to particular promoter-vector combinations, especially in regulatory jurisdictions where patent claims remain enforceable.
Summary table of claims focus and patent landscape
| Aspect |
Description |
Patent Landscape Context |
| Claim breadth |
Tissue-specific promoter + vector + therapeutic gene |
Narrow but enforceable |
| Vector types |
Viral (adenoviral, lentiviral), non-viral elements |
Overlaps with multiple patents |
| Application focus |
Gene therapy, tissue targeting |
Competes with broader delivery system patents |
| Relevance to current tech |
Moderate; focus on promoter specificity remains; newer vectors less encumbered |
Decreasing relevance but still valuable for specific targeting claims |
Key Takeaways
- US 6,734,164 claims a tissue-specific gene delivery method with narrow scope.
- Its claims focus on promoter and vector configurations for targeted gene therapy.
- The patent landscape in gene delivery features dense overlapping rights, particularly around vectors and promoter elements.
- Its enforceability is clear but limited to specific vector-promoter combinations.
- Evolving vector technologies diminish its direct applicability but do not negate its strategic value.
FAQs
1. Does US Patent 6,734,164 cover all gene therapy vectors?
No. It claims specific configurations involving certain promoters and vector types, not all gene delivery systems.
2. Is the patent still enforceable today?
Yes, unless invalidated in court or expired in specific jurisdictions. It is enforceable in the U.S. through 2024, assuming maintenance fees are paid.
3. Can this patent be licensed or challenged?
Yes. It has been licensed; challenges would focus on prior art or invalidity arguments related to its claims.
4. How does this patent impact research?
It may restrict use of specific promoter-vector combinations unless licensed or unless the claims are designed around.
5. What are emerging alternatives to the technologies claimed here?
Lipid nanoparticles, non-viral vectors, and gene editing techniques like CRISPR-Cas9 do not depend on the specific configurations claimed and are gaining market share.
References
- Fitzgerald, J. (1999). US Patent 5,994,077. Gene delivery system.
- Ghosh, A. (2001). US Patent 6,194,347. Targeted gene delivery vectors.
- United States Patent and Trademark Office. (2004). Patent 6,734,164.
